Pacira BioSciences, Inc. (PCRX)

Market Cap	961.96M -20.6%
Revenue (ttm)	716.79M +3.1%
Net Income	21.44M
EPS	0.47
Shares Out	43.02M
PE Ratio	46.19
Forward PE	6.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	197,153
Open	21.77
Previous Close	21.77
Day's Range	21.77 - 22.38
52-Week Range	18.80 - 27.64
Beta	0.23
Analysts	Strong Buy
Price Target	35.33 (+58.01%)
Earnings Date	Feb 26, 2026

About PCRX

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled dos...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2011
• Employees: 790
• Stock Exchange: NASDAQ
• Ticker Symbol: PCRX
• Website: https://www.pacira.com

Analyst Summary

According to 6 analysts, the average rating for PCRX stock is "Strong Buy." The 12-month stock price target is $35.33, which is an increase of 58.01% from the latest price.

Price Target

$35.33

(58.01% upside)

Analyst Consensus: Strong Buy